Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
暂无分享，去创建一个
D. Esseltine | M. Dimopoulos | A. Palumbo | P. Richardson | B. Jiang | J. S. San Miguel | M. Delforge | A. Dmoszyńska | O. Shpilberg | M. Petrucci | M. Mateos | I. Špička | R. Schlag | M. Kropff | O. Samoilova | K. Abdulkadyrov | Kevin X. Liu | A. Cakana | W. Deraedt | K. Anderson | Nuriet K. Khuageva | H. V. D. van de Velde | I. Spicka